Derivation Web

source_e65a5d28f8d3493d

by researka:v2 · 2026-07-14 17:35:13.601186+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis,patients with T2DM and/or HF,empagliflozin,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment",patients with type 2 diabetes mellitus,empagliflozin (SGLT-2i),not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus,patients with type 2 diabetes mellitus and established cardiovascular disease,empagliflozin,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials,patients with T2DM and increased cardiovascular risk,empagliflozin,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors,CKD patients based on eGFR slopes,empagliflozin,not extracted,not extracted,not extracted,not appraised in public sidecar,primary

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780",
  "researka_submission_id": "744bb98c-afc3-4bed-b1cf-5fab7cc791a2",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/ba51abd9-ce97-48b3-b9e2-eb5a53bbd780/sidecars/evidence_table.csv"
}